Title: Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial
journal:Journal of Clinical Oncology
Authors:Kevin Kalinsky; Melissa K. Accordino; Codruta Chiuzan; Prabhjot S. Mundi; Elizabeth Sakach; Claire Sathe; Heejoon Ahn; Meghna S. Trivedi; Yelena Novik; Amy Tiersten; George Raptis; Lea N. Baer; Sun Y. Oh; Amelia B. Zelnak; Kari B. Wisinski; Eleni Andreopoulou; William J. Gradishar; Erica Stringer-Reasor; Sonya A. Reid; Anne O'Dea; Ruth O'Regan; Katherine D. Crew; Dawn L. Hershman
Published date:2023-8-20
DOI:10.1200/jco.22.02392
PDF link:https://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.02392
Article link:http://dx.doi.org/10.1200/jco.22.02392
Article Source:American Society of Clinical Oncology (ASCO)。
Remark: |